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Abstract
Chemokine signaling is essential for coordinated cell migration in health and
disease to specifically govern cell positioning in space and time. Typically,
chemokines signal through heptahelical, G protein-coupled receptors to
orchestrate cell migration. Notably, chemokine receptors are highly dynamic
structures and signaling efficiency largely depends on the discrete contact with
the ligand. Promiscuity of both chemokines and chemokine receptors,
combined with biased signaling and allosteric modulation of receptor activation,
guarantees a tightly controlled recruitment and positioning of individual cells
within the local environment at a given time. Here, we discuss recent insights in
understanding chemokine gradient formation by atypical chemokine receptors
and how typical chemokine receptors can transmit distinct signals to translate
guidance cues into coordinated cell locomotion in space and time.
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Chemokine-induced signaling
Soon after chemokines were discovered in the late ’80s1–3, 
it was shown that their cognate receptors on cell surfaces were 
members of the rhodopsin-like family of G protein–coupled 
receptors (GPCRs). The sensitivity of intracellular signaling to 
pertussis toxin indicated that the putative receptor for the orphan 
ligand CXCL8 (formerly interleukin-8[IL-8]) expressed on human 
neutrophils couples to the Gi class of heterotrimeric proteins4. 
A few years later, the receptors CXCR1 and CXCR2 were iden-
tified, cloned, and expressed on mammalian cells for studying 
signaling properties5,6. Despite their high sequence identity 
(almost 80%), ligand selectivity is different for the receptors. 
CXCL8, CXCL5, and CXCL6 bind to both CXCR1 and 
CXCR2, but the latter also binds the chemokines CXCL1-3 and 
CXCL77 with high affinity. Hence, chemokines can bind multiple 
receptors, and on the other side receptors are not always 
selective for one specific chemokine. Moreover, CXCR1 and 
CXCR2 differ in their capacity to induce cellular responses upon 
stimulation with CXCL8. Both receptors stimulate intracellular 
calcium fluxes, chemotaxis, and degranulation; however, only 
CXCR1 stimulation leads to activation of phospholipase D 
and the respiratory burst in human neutrophils7,8. These early 
observations not only indicated a promiscuity within the chem-
okine system but also revealed that the GPCRs have the ability to 
couple differently to downstream signaling pathways. Moreover, 
a given chemokine can stimulate different responses depending 
on the receptor to which it binds as well as on the cells where 
the receptors are expressed.
Typically, chemokine receptor stimulation leads to the GDP/
GTP exchange of coupled heterotrimeric Gi proteins and the 
subsequent dissociation of the βγ subunits, which then activate 
phosphoinositide-specific phospholipase Cβ (PLC) and phosph-
oinositide 3-kinase (PI3K). PLC produces inositol-trisphosphate 
(IP3) and diacylglycerol (DAG). IP3 triggers calcium mobilization 
whereas DAG activates protein kinase C (PKC). PI3K generates 
3-phosphoinositides, which serve as anchors in the recruitment 
of proteins with pleckstrin homology domains to the plasma 
membrane, such as AKT/PKB9. Although these signaling 
events are common to all chemokine receptors, it is well known 
that the activation of further downstream pathways is quite 
different. This may depend on the efficacy with which a 
chemokine triggers its receptor, giving rise to different spatial and 
temporal signal fluxes. Such biased signaling at the chemokine 
receptor was recently revealed by using biosensors to demonstrate 
differences in G-protein subclass coupling of CCR2, CCR5, and 
CCR710. Other important considerations are the surface expression 
and density of a receptor and the specific cellular context. As 
an example, the second ligand of CCR7 CCL19, in contrast 
to CCL21, does not attract T cells in a microfluidic migration 
assay under flow conditions11 but does efficiently stimulate migra-
tion of cells transfected with the receptor12,13, dendritic cells14,15, or 
T cells in static migration assays16. Moreover, monocyte-derived 
dendritic cells express CCR7 on the cell surface but migrate 
toward CCL19 and CCL21 only when matured in the pres-
ence of prostaglandin E217,18. A recent observation indicates that 
GPCRs move within restricted areas of the cell surface. These 
membrane subdomains are maintained by “fences” created by 
the cytoskeleton and “pickets” made of transmembrane proteins. 
At special hot spots, GPCRs and G proteins are retained and 
preferentially couple19,20. These findings imply that signaling 
by GPCRs can be confined on the cell surface and may depend 
on the local availability of downstream interaction partners.
Signal bias
Several observations indicate that chemokine receptors may not 
exclusively couple and signal through G proteins but interact 
with additional signaling mediators, such as β-arrestins. 
Upon activation, GPCRs become desensitized through phospho-
rylation of their intracellular C-termini by second messenger– 
dependent kinases and GPCR kinases (GRKs). The phosphorylation 
pattern, also known as barcode, induces arrestin 
recruitment to the receptor21,22. However, depending on the ligand- 
mediated stimulation, the recruited β-arrestins cause receptor 
inactivation and internalization or the receptor-bound arrestin 
acts as a scaffold which leads to the recruitment and activation 
of protein kinases23–27. An early definition suggested that agonists 
which induce receptor internalization are considered G protein–
biased but that those which trigger arrestin-dependent signaling 
are called β-arrestin–biased22. A more complete view of biased 
signaling takes into account that signal bias can depend on the 
ligand (ligand bias), the receptor (receptor bias), and the con-
text (tissue bias)28,29. For CXCR4, it was shown that monomeric 
and dimeric forms of CXCL12, which both may exist under 
physiological conditions30, induce selective signal transduction 
pathways and differ in β-arrestin recruitment26,27. Whereas dimeric 
CXCL12 does not induce β-arrestin recruitment and chemo-
taxis, both monomeric and dimeric forms of CXCL12 equally 
trigger the activation of ERK26. For CCR7, CCL19 binding 
results in robust serine/threonine phosphorylation of the recep-
tor and β-arrestin recruitment catalyzed by GRK3 and GRK6, 
whereas CCL21 binding activates GRK6 alone31. Consequently, 
CCL19 induces rapid CCR7 internalization whereas CCL21 
hardly does32 and hence can be seen as ligand bias15. Notably, GRK6 
contributes to haptotactic sensing of CCL21 gradients at least 
by dendritic cells33.
Ogilvie et al. showed that CCR2 can activate distinct 
cellular responses depending on the chemokine which binds 
to the receptor34. Also, this observation can be seen as ligand 
bias; however, it does not depend on receptor phosphorylation. 
Whereas CCL2 induces all typical responses when used to 
stimulate CCR2, such as calcium fluxes, actin polymerization, 
and chemotaxis, CCL11 instead was shown in binding assays 
to act as an antagonist and to suppress CCL2-induced signaling35. 
More detailed analysis revealed that CCL11 triggered pertussis 
toxin-sensitive ERK phosphorylation downstream of CCR2 with-
out inducing GDP/GTP exchange of the G protein or leading to 
receptor phosphorylation. Activation of ERK was required to 
antagonize CCL2-mediated signaling by CCR2. Both chemokines 
stimulated PI3K; however, CCL2 stimulated the βγ-dependent 
PI3Kγ isoform whereas CCL11 activated a p85/p110 
isoform34. In general, ligand binding to GPCRs induces the rear-
rangement of the transmembrane helices36. The above observations 
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are consistent with a view where CCL2 and CCL11 induce 
different conformations of CCR2, which translate to diverse 
intracellular coupling.
Binding of CXCL10 to CXCR3 drives T helper 1 (Th1) 
polarization via STAT1, 4, and 5 phosphorylation, whereas 
CXCL11 induces a Th2 and regulatory T (Treg) (IL-10hi) fate 
involving p70 kinase/mTOR and STAT 3 and 637. The marked 
differences in T-cell polarization could be explained by the 
chemokine-specific signaling. In an early study, which did not 
investigate T-cell fate, it was shown that the three ligands of 
CXCR3 (namely CXCL9, CXCL10, and CXCL11) induce 
typical responses such as calcium mobilization and chemotaxis. 
By contrast, upon stimulation, CXCR3 internalization was most 
prominent with CXCL11 whereas CXCL9 and CXCL10 showed 
only moderate effects. The differences were explained with the 
use of distinct entities of the intracellular domains of CXCR3 
to transmit the responses when stimulated with CXCL9 and 
CXCL10 versus CXCL1138. More recently, it was shown that 
CXCL11 and, to a lesser extent, CXCL10, but not CXCL9, 
induce β-arrestin2 recruitment39. Interestingly, more pronounced 
differences were reported for β-arrestin recruitment and the 
binding modality to the two splice variants CXCR3A and 
CXCR3B, which differ by a 51–amino acid extension at the extra-
cellular N-terminus of CXCR3B25,39. However, expression of the 
putative CXCR3B in mouse tissue is not clear and this is 
due to an in-frame stop codon in the coding exon40. These 
observations confirm that intracellular coupling efficiency of 
the receptor can be modulated by extracellular ligand binding.
Modulation of chemokine receptor signaling
Chemokine activity on cognate receptors can be modulated in 
multiple ways. The nuclear protein HMGB1, which is released 
by necrotic or severely stressed cells, binds TLR4 and RAGE 
but not chemokine receptors. However, HMGB1 forms het-
erocomplexes with CXCL12, which stimulate CXCR4 with 
higher potency than the chemokine alone41. Moreover, chem-
okines can act synergistically, increasing their potency and 
efficacy of receptor activation42–44. In addition, chemokine 
receptors, when triggered with two chemokines, can display 
allosteric regulation. For example, CXCL14 binds CXCR4 
with high affinity but does not stimulate any typical receptor- 
mediated response. Nevertheless, CXCL14 markedly enhances 
the potency and efficacy of CXCL12 on CXCR445.
Direct interaction of chemokine receptors with G proteins, 
GRKs, and β-arrestin is amply reported. In addition, second- 
messenger kinases, such as PKC and PKA, phosphorylate serine 
and threonine residues at the C-termini of chemokine receptors. 
However, some chemokine receptors were shown to directly bind 
and activate additional proteins, giving rise to receptor-specific 
activation of signal transduction. CXCR4 interacts with the 
eukaryotic translation initiation factor eIF2B, suggesting that the 
receptor may stimulate local protein synthesis46. Indeed, mesen-
chymal cells were shown to de novo synthesize actin in the cell 
periphery47,48. CCR7, when oligomerized, is able to bind and 
activate an Src kinase signaling pathway which leads to tyro-
sine phosphorylation within its DRY motif, which then serves as 
a docking site for SH2 domain–containing molecules such 
as phosphatase SHP249. Similarly, the kinase JAK2 was shown 
to phosphorylate CCR2B upon stimulation with CCL250. 
Another direct interaction is the binding of VASP to CXCR2 
necessary to mediate CXCL8-stimulated cell migration51. 
The interaction of FROUNT with CCR2 and CCR5 enhances 
migration of monocytes and macrophages by increasing 
consolidated pseudopodium formation52,53.
Chemokine presentation
The chemokine system is well known to orchestrate leuko-
cyte migration through the formation of chemotactic gradients. 
It should be noted that such chemotactic gradients are locally 
confined, not exceeding 100–150 µm54. Local confinement implies 
that chemokines are retained on cell surfaces and the extracel-
lular matrix55. Glycosaminoglycan (GAG) binding sites can be 
found in all chemokines and were shown to be essential to mediate 
the binding to proteoglycans. Binding of chemokines to GAGs 
can modify their activities, enhancing or reducing their potency 
on cognate receptors55,56. On the other side, GAG binding can 
increase local chemokine concentrations (for example, in recep-
tor vicinity) and efficiently present the ligands for haptotacic 
chemokine receptor-mediated migration of cells. Secondary 
B-cell follicles are characterized by germinal centers (GCs) 
where B-cell antibody affinity maturation occurs. The GCs are 
split into the CXCL12-rich dark zone, where B-cell centroblasts 
proliferate, and the CXCL13-rich light zone, where centrocytes 
are selected for antigen affinity57. Specific stroma cells, the 
CXCL12-expressing reticulate cells (CRCs), produce CXCL12 
in the dark zone58, whereas follicular dendritic cells release 
CXCL13 in the light zone59. During affinity maturation, B cells 
move between the two compartments of the GC, being attracted 
reciprocally by the two chemokines57. In transgenic ani-
mals which express CXCL12 lacking GAG binding sites, the 
dark zone is enlarged and poorly defined, consistent with the 
notion that CXCL12 needs to be locally retained to maintain the 
structure of the GC, which is not surrounded by physical 
borders60. Similarly, CXCL13 can bind to GAGs without 
losing its capability to bind to CXCR5, being able to promote 
adhesion-dependent cell migration61. However, additional 
mechanisms, which attenuate B-cell migration at the periphery 
of GCs, were shown to be essential for efficient B maturation 
and GC integrity62.
Atypical chemokine receptors
An important consideration for the generation and 
maintenance of biological gradients was made by Francis Crick, 
who proposed that, in apposition to a source of a morphogen, a 
sink must exist in order to prevent the gradient from blurring63. 
Cells migrating on chemokine gradients scavenge the ligands 
from the surrounding medium and in this way presumably con-
tribute to gradient maintenance64. In addition, the group of 
atypical chemokine receptors (ACKRs), which share the seven- 
transmembrane domain topology of conventional chemokine 
receptors but do not couple to G proteins and fail to induce 
typical intracellular signaling, act as scavengers targeting 
chemokines for lysosomal degradation65,66. ACKR4 (formerly 
CCRL1), a scavenger of the chemokines CCL19, CCL21, and 
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CCL25, is expressed on the lymphatic endothelium (LECs) of 
subcapsular sinuses (SCSs) of lymph nodes. In the SCSs, the 
expression of ACKR4 is asymmetric, being present on LECs 
forming the ceiling of the SCSs but not on those on the floor 
facing the interfollicular areas. The asymmetric distribution 
generates CCL21 gradients pointing from the SCS across the 
floor LECs into the interfollicular areas67. This CCL21 gradient 
is assumed to be critical for dendritic cell and T-cell emigration 
from SCSs into the parenchyma of lymph nodes. For ACKR3, a 
scavenger for the chemokines CXCL11 and CXCL1268, it 
was shown, in zebrafish lateral line primordium as a model, 
that the migrating cell collectives can self-generate CXCL12 
gradients across their length69,70. In humans, ACKR3 is upregu-
lated on B cells at the plasmablast stage, when cells downregu-
late CXCR5 and exit the GCs71. Because ACKR3 has about a 
10-fold higher affinity for CXCL12 than CXCR4, it was 
concluded that expression of the scavenger renders the cells less 
sensitive to CXC12-mediated retention via CXCR4 in the 
GCs allowing egress. Indeed, migration of plasmablast toward 
CXCL12 is markedly reduced but can be rescued upon attenuation 
of ACKR371.
Signaling through the chemokine system not only plays a role 
in hematopoietic cells but also is present in mesenchymal 
cells. Chemokine signaling is required during development in 
the central nervous system72–74. ACKR3 was shown to be 
critical for the migration of interneurons in mouse brain develop-
ment. The role of the scavenger appears to lie in the control of the 
level of CXCL12. In the absence of the scavenger, excess of 
CXCL12 leads to the downregulation of CXCR4 which causes 
the attenuation of interneuron migration75,76. The chemokine 
system also plays a pivotal role in angiogenesis, where 
chemokines induce cell growth and stimulate the recruitment 
of endothelial cells66. The properties of the chemokine system 
have been adopted by many neoplasms. Several lines of evi-
dence indicate that metastatic infiltration of distant organs such as 
the bone marrow, lung, and liver is mediated by chemokines and 
their cognate receptors77–79. In a recent study80, the infiltrating 
properties of human diffuse large B-cell lymphomas (DLBCLs) 
into distant organs in a disseminated mouse xenograft model 
were tested. While organ infiltration is assumed to depend on 
CXCR4-mediated migration, expression of ACKR3 appeared 
to play a critical role. In the absence of the scavenger, the DLB-
CLs fail to infiltrate the organs. In vitro studies suggest that 
ACKR3 is required to generate local CXCL12 gradients during 
extravasation80.
Conclusions
Although all typical chemokine receptors expressed on 
leukocyte are able to induce cell migration, the signaling mecha-
nisms downstream of the receptors are not unified. Rather, 
a complex signaling network composed of biased signaling, pro-
miscuous signaling, and signal specificity paired with chemokine 
presentation and scavenging contributes to chemokine-stimulated 
cell migration. Such fine tuning is important to allow specific 
and efficient migration (for example, during immune responses) 
to guarantee precise spatiotemporal localization of individual 
effector cells.
Competing interests
The authors declare that they have no competing interests.
Grant information
This work was supported by the Swiss National Science 
Foundation (grants 169936 and 163336 and Sinergia CRSII3_
160719), the Thurgauische Stiftung für Wissenschaft und 
Forschung, the Helmut Horten Foundation, and the State 
Secretariat for Education, Research and Innovation. 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
References F1000 recommended
1. Walz A, Peveri P, Aschauer H, et al.: Purification and amino acid sequencing 
of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem 
Biophys Res Commun. 1987; 149(2): 755–61.  
PubMed Abstract | Publisher Full Text 
2. Yoshimura T, Matsushima K, Oppenheim JJ, et al.: Neutrophil chemotactic factor 
produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear 
leukocytes: partial characterization and separation from interleukin 1 (IL 1).  
J Immunol. 1987; 139(3): 788–93.  
PubMed Abstract 
3. Luster AD, Unkeless JC, Ravetch JV: Gamma-interferon transcriptionally 
regulates an early-response gene containing homology to platelet proteins. 
Nature. 1985; 315(6021): 672–6.  
PubMed Abstract | Publisher Full Text 
4. Thelen M, Peveri P, Kernen P, et al.: Mechanism of neutrophil activation by NAF, 
a novel monocyte-derived peptide agonist. FASEB J. 1988; 2(11): 2702–6.  
PubMed Abstract 
5. Holmes WE, Lee J, Kuang WJ, et al.: Structure and functional expression of a 
human interleukin-8 receptor. Science. 1991; 253(5025): 1278–80.  
PubMed Abstract | Publisher Full Text 
6. Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional 
human interleukin-8 receptor. Science. 1991; 253(5025): 1280–3.  
PubMed Abstract | Publisher Full Text 
7. Murphy PM, Baggiolini M, Charo IF, et al.: International union of pharmacology. 
XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000; 52(1): 
145–76.  
PubMed Abstract 
8. Jones SA, Wolf M, Qin S, et al.: Different functions for the interleukin 8 
receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and 
phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad 
Sci U S A. 1996; 93(13): 6682–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Thelen M: Dancing to the tune of chemokines. Nat Immunol. 2001; 2(2): 129–34. 
PubMed Abstract | Publisher Full Text 
10.  Corbisier J, Galès C, Huszagh A, et al.: Biased signaling at chemokine 
receptors. J Biol Chem. 2015; 290(15): 9542–54.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
11. Nandagopal S, Wu D, Lin F: Combinatorial guidance by CCR7 ligands for  
Page 5 of 8
F1000Research 2018, 7(F1000 Faculty Rev):95 Last updated: 15 AUG 2018
T lymphocytes migration in co-existing chemokine fields. PLoS One. 2011; 
6(3): e18183.  
PubMed Abstract | Publisher Full Text | Free Full Text 
12. Yoshida R, Nagira M, Kitaura M, et al.: Secondary lymphoid-tissue chemokine 
is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998; 
273(12): 7118–22.  
PubMed Abstract | Publisher Full Text 
13. Otero C, Eisele PS, Schaeuble K, et al.: Distinct motifs in the chemokine 
receptor CCR7 regulate signal transduction, receptor trafficking and 
chemotaxis. J Cell Sci. 2008; 121(Pt 16): 2759–67.  
PubMed Abstract | Publisher Full Text 
14. Ricart BG, John B, Lee D, et al.: Dendritic cells distinguish individual 
chemokine signals through CCR7 and CXCR4. J Immunol. 2011; 186(1): 53–61.  
PubMed Abstract | Publisher Full Text 
15. Hauser MA, Legler DF: Common and biased signaling pathways of the 
chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in 
leukocytes. J Leukoc Biol. 2016; 99(6): 869–82.  
PubMed Abstract 
16. Schaeuble K, Hauser MA, Singer E, et al.: Cross-talk between TCR and CCR7 
signaling sets a temporal threshold for enhanced T lymphocyte migration.  
J Immunol. 2011; 187(11): 5645–52.  
PubMed Abstract | Publisher Full Text 
17. Scandella E, Men Y, Legler DF, et al.: CCL19/CCL21-triggered signal 
transduction and migration of dendritic cells requires prostaglandin E2. Blood. 
2004; 103(5): 1595–601.  
PubMed Abstract | Publisher Full Text 
18. Legler DF, Krause P, Scandella E, et al.: Prostaglandin E2 is generally required 
for human dendritic cell migration and exerts its effect via EP2 and EP4 
receptors. J Immunol. 2006; 176(2): 966–73.  
PubMed Abstract | Publisher Full Text 
19. Kusumi A, Shirai YM, Koyama-Honda I, et al.: Hierarchical organization of 
the plasma membrane: investigations by single-molecule tracking vs. 
fluorescence correlation spectroscopy. FEBS Lett. 2010; 584(9): 1814–23.  
PubMed Abstract | Publisher Full Text 
20.  Sungkaworn T, Jobin ML, Burnecki K, et al.: Single-molecule imaging 
reveals receptor-G protein interactions at cell surface hot spots. Nature. 2017; 
550(7677): 543–7.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
21.  Nobles KN, Xiao K, Ahn S, et al.: Distinct phosphorylation sites on the 
β2-adrenergic receptor establish a barcode that encodes differential functions 
of β-arrestin. Sci Signal. 2011; 4(185): ra51.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
22. Reiter E, Ahn S, Shukla AK, et al.: Molecular mechanism of β-arrestin-biased 
agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012; 
52: 179–97.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Hauser MA, Kindinger I, Laufer JM, et al.: Distinct CCR7 glycosylation pattern 
shapes receptor signaling and endocytosis to modulate chemotactic 
responses. J Leukoc Biol. 2016; 99(6): 993–1007.  
PubMed Abstract | Publisher Full Text 
24.  Luo J, Busillo JM, Stumm R, et al.: G Protein-Coupled Receptor Kinase 3 and 
Protein Kinase C Phosphorylate the Distal C-Terminal Tail of the Chemokine 
Receptor CXCR4 and Mediate Recruitment of β-Arrestin. Mol Pharmacol. 2017; 
91(6): 554–66.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
25. Smith JS, Alagesan P, Desai NK, et al.: C-X-C Motif Chemokine Receptor 3 
Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream 
Signaling Pathways. Mol Pharmacol. 2017; 92(2): 136–50.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Ziarek JJ, Kleist AB, London N, et al.: Structural basis for chemokine recognition 
by a G protein-coupled receptor and implications for receptor activation. Sci 
Signal. 2017; 10(471): pii: eaah5756.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Drury LJ, Ziarek JJ, Gravel S, et al.: Monomeric and dimeric CXCL12 inhibit 
metastasis through distinct CXCR4 interactions and signaling pathways. Proc 
Natl Acad Sci U S A. 2011; 108(43): 17655–60.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Steen A, Larsen O, Thiele S, et al.: Biased and g protein-independent signaling 
of chemokine receptors. Front Immunol. 2014; 5: 277.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Karin N, Wildbaum G, Thelen M: Biased signaling pathways via CXCR3 control 
the development and function of CD4+ T cell subsets. J Leukoc Biol. 2016; 99(6): 
857–62.  
PubMed Abstract | Publisher Full Text 
30. Ziarek JJ, Veldkamp CT, Zhang F, et al.: Heparin oligosaccharides inhibit 
chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding 
orthogonal to the dimerization interface, promoting oligomerization, and 
competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus.  
J Biol Chem. 2013; 288(1): 737–46.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Zidar DA, Violin JD, Whalen EJ, et al.: Selective engagement of G protein 
coupled receptor kinases (GRKs) encodes distinct functions of biased 
ligands. Proc Natl Acad Sci U S A. 2009; 106(24): 9649–54.  
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Otero C, Groettrup M, Legler DF: Opposite fate of endocytosed CCR7 and its 
ligands: recycling versus degradation. J Immunol. 2006; 177(4): 2314–23.  
PubMed Abstract | Publisher Full Text 
33.  Schwarz J, Bierbaum V, Vaahtomeri K, et al.: Dendritic Cells Interpret 
Haptotactic Chemokine Gradients in a Manner Governed by Signal-to-Noise 
Ratio and Dependent on GRK6. Curr Biol. 2017; 27(9): 1314–25.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
34. Ogilvie P, Thelen S, Moepps B, et al.: Unusual chemokine receptor antagonism 
involving a mitogen-activated protein kinase pathway. J Immunol. 2004; 
172(11): 6715–22.  
PubMed Abstract | Publisher Full Text 
35. Ogilvie P, Bardi G, Clark-Lewis I, et al.: Eotaxin is a natural antagonist for CCR2 
and an agonist for CCR5. Blood. 2001; 97(7): 1920–4.  
PubMed Abstract | Publisher Full Text 
36. Schwartz TW, Frimurer TM, Holst B, et al.: Molecular mechanism of 7TM receptor 
activation-a global toggle switch model. Annu Rev Pharmacol Toxicol. 2006; 46: 
481–519.  
PubMed Abstract | Publisher Full Text 
37. Zohar Y, Wildbaum G, Novak R, et al.: CXCL11-dependent induction of FOXP3-
negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin 
Invest. 2014; 124(5): 2009–22.  
PubMed Abstract | Publisher Full Text | Free Full Text 
38. Colvin RA, Campanella GS, Sun J, et al.: Intracellular domains of CXCR3 that 
mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem. 2004; 279(29): 
30219–27.  
PubMed Abstract | Publisher Full Text 
39. Berchiche YA, Sakmar TP: CXC Chemokine Receptor 3 Alternative Splice 
Variants Selectively Activate Different Signaling Pathways. Mol Pharmacol. 
2016; 90(4): 483–95.  
PubMed Abstract | Publisher Full Text 
40. Campanella GS, Colvin RA, Luster AD: CXCL10 can inhibit endothelial cell 
proliferation independently of CXCR3. PLoS One. 2010; 5(9): e12700.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Schiraldi M, Raucci A, Muñoz LM, et al.: HMGB1 promotes recruitment of 
inflammatory cells to damaged tissues by forming a complex with CXCL12 
and signaling via CXCR4. J Exp Med. 2012; 209(3): 551–63.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Kuscher K, Danelon G, Paoletti S, et al.: Synergy-inducing chemokines enhance 
CCR2 ligand activities on monocytes. Eur J Immunol. 2009; 39(4): 1118–28.  
PubMed Abstract | Publisher Full Text 
43. Paoletti S, Petkovic V, Sebastiani S, et al.: A rich chemokine environment 
strongly enhances leukocyte migration and activities. Blood. 2005; 105(9): 
3405–12.  
PubMed Abstract | Publisher Full Text 
44. Gouwy M, Struyf S, Noppen S, et al.: Synergy between coproduced CC and CXC 
chemokines in monocyte chemotaxis through receptor-mediated events. Mol 
Pharmacol. 2008; 74(2): 485–95.  
PubMed Abstract | Publisher Full Text 
45. Collins PJ, McCully ML, Martínez-Muñoz L, et al.: Epithelial chemokine CXCL14 
synergizes with CXCL12 via allosteric modulation of CXCR4. FASEB J. 2017; 
31(7): 3084–97.  
PubMed Abstract | Publisher Full Text | Free Full Text 
46. Palmesino E, Apuzzo T, Thelen S, et al.: Association of eukaryotic translation 
initiation factor eIF2B with fully solubilized CXCR4. J Leukoc Biol. 2016; 99(6): 
971–8.  
PubMed Abstract | Publisher Full Text 
47. Kislauskis EH, Zhu X, Singer RH: Sequences responsible for intracellular 
localization of beta-actin messenger RNA also affect cell phenotype. J Cell 
Biol. 1994; 127(2): 441–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
48.  Hüttelmaier S, Zenklusen D, Lederer M, et al.: Spatial regulation of beta-
actin translation by Src-dependent phosphorylation of ZBP1. Nature. 2005; 
438(7067): 512–5.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
49. Hauser MA, Schaeuble K, Kindinger I, et al.: Inflammation-Induced CCR7 
Oligomers Form Scaffolds to Integrate Distinct Signaling Pathways for 
Efficient Cell Migration. Immunity. 2016; 44(1): 59–72.  
PubMed Abstract | Publisher Full Text 
50. Mellado M, Rodríguez-Frade JM, Aragay A, et al.: The chemokine monocyte 
chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine 
phosphorylation of the CCR2B receptor. J Immunol. 1998; 161(2): 805–13.  
PubMed Abstract 
51. Neel NF, Barzik M, Raman D, et al.: VASP is a CXCR2-interacting protein that 
regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci. 2009; 
122(Pt 11): 1882–94.  
PubMed Abstract | Publisher Full Text | Free Full Text 
52. Toda E, Terashima Y, Sato T, et al.: FROUNT is a common regulator of CCR2 
and CCR5 signaling to control directional migration. J Immunol. 2009; 183(10): 
6387–94.  
PubMed Abstract | Publisher Full Text 
53.  Terashima Y, Onai N, Murai M, et al.: Pivotal function for cytoplasmic 
protein FROUNT in CCR2-mediated monocyte chemotaxis. Nat Immunol. 2005; 
6(8): 827–35.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
Page 6 of 8
F1000Research 2018, 7(F1000 Faculty Rev):95 Last updated: 15 AUG 2018
54.  Weber M, Hauschild R, Schwarz J, et al.: Interstitial dendritic cell guidance 
by haptotactic chemokine gradients. Science. 2013; 339(6117): 328–32.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
55.  Proudfoot AEI, Johnson Z, Bonvin P, et al.: Glycosaminoglycan Interactions 
with Chemokines Add Complexity to a Complex System. Pharmaceuticals 
(Basel). 2017; 10(3): pii: E70. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
56.  Proost P, Struyf S, van Damme J, et al.: Chemokine isoforms and 
processing in inflammation and immunity. J Autoimmun. 2017; 85: 45–57.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
57. Victora GD, Nussenzweig MC: Germinal centers. Annu Rev Immunol. 2012; 30: 
429–57.  
PubMed Abstract | Publisher Full Text 
58.  Rodda LB, Bannard O, Ludewig B, et al.: Phenotypic and Morphological 
Properties of Germinal Center Dark Zone Cxcl12-Expressing Reticular Cells.  
J Immunol. 2015; 195(10): 4781–91.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
59.  Wang X, Cho B, Suzuki K, et al.: Follicular dendritic cells help establish 
follicle identity and promote B cell retention in germinal centers. J Exp Med. 
2011; 208(12): 2497–510.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
60.  Barinov A, Luo L, Gasse P, et al.: Essential role of immobilized chemokine 
CXCL12 in the regulation of the humoral immune response. Proc Natl Acad Sci 
U S A. 2017; 114(9): 2319–24.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
61.  Monneau YR, Luo L, Sankaranarayanan NV, et al.: Solution structure of 
CXCL13 and heparan sulfate binding show that GAG binding site and cellular 
signalling rely on distinct domains. Open Biol. 2017; 7(10): pii: 170133.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
62.  Muppidi JR, Lu E, Cyster JG: The G protein-coupled receptor P2RY8 and 
follicular dendritic cells promote germinal center confinement of B cells, 
whereas S1PR3 can contribute to their dissemination. J Exp Med. 2015; 
212(13): 2213–22.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
63. Crick F: Diffusion in embryogenesis. Nature. 1970; 225(5231): 420–2.  
PubMed Abstract | Publisher Full Text 
64. Volpe S, Cameroni E, Moepps B, et al.: CCR2 acts as scavenger for CCL2 during 
monocyte chemotaxis. PLoS One. 2012; 7(5): e37208.  
PubMed Abstract | Publisher Full Text | Free Full Text 
65. Bachelerie F, Graham GJ, Locati M, et al.: New nomenclature for atypical 
chemokine receptors. Nat Immunol. 2014; 15(3): 207–8.  
PubMed Abstract | Publisher Full Text 
66. Bachelerie F, Ben-Baruch A, Burkhardt AM, et al.: International Union of Basic 
and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended 
family of chemokine receptors and introducing a new nomenclature for 
atypical chemokine receptors. Pharmacol Rev. 2014; 66(1): 1–79.  
PubMed Abstract | Publisher Full Text | Free Full Text 
67.  Ulvmar MH, Werth K, Braun A, et al.: The atypical chemokine receptor 
CCRL1 shapes functional CCL21 gradients in lymph nodes. Nat Immunol. 2014; 
15(7): 623–30.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
68. Naumann U, Cameroni E, Pruenster M, et al.: CXCR7 functions as a scavenger 
for CXCL12 and CXCL11. PLoS One. 2010; 5(2): e9175.  
PubMed Abstract | Publisher Full Text | Free Full Text 
69.  Donà E, Barry JD, Valentin G, et al.: Directional tissue migration through a 
self-generated chemokine gradient. Nature. 2013; 503(7475): 285–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
70. Venkiteswaran G, Lewellis SW, Wang J, et al.: Generation and dynamics of an 
endogenous, self-generated signaling gradient across a migrating tissue. Cell. 
2013; 155(3): 674–87.  
PubMed Abstract | Publisher Full Text | Free Full Text 
71. Humpert ML, Pinto D, Jarrossay D, et al.: CXCR7 influences the migration of B 
cells during maturation. Eur J Immunol. 2014; 44(3): 694–705.  
PubMed Abstract | Publisher Full Text 
72. Nagasawa T, Nakajima T, Tachibana K, et al.: Molecular cloning and 
characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-
derived factor 1 receptor, a murine homolog of the human immunodeficiency 
virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A. 1996; 93(25): 14726–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
73. Nagasawa T, Hirota S, Tachibana K, et al.: Defects of B-cell lymphopoiesis and 
bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. 
Nature. 1996; 382(6592): 635–8.  
PubMed Abstract | Publisher Full Text 
74. Ma Q, Jones D, Borghesani PR, et al.: Impaired B-lymphopoiesis, myelopoiesis, 
and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. 
Proc Natl Acad Sci U S A. 1998; 95(16): 9448–53.  
PubMed Abstract | Publisher Full Text | Free Full Text 
75.  Sánchez-Alcañiz JA, Haege S, Mueller W, et al.: Cxcr7 controls neuronal 
migration by regulating chemokine responsiveness. Neuron. 2011; 69(1): 
77–90.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
76. Abe P, Mueller W, Schütz D, et al.: CXCR7 prevents excessive CXCL12-mediated 
downregulation of CXCR4 in migrating cortical interneurons. Development. 
2014; 141(9): 1857–63.  
PubMed Abstract | Publisher Full Text 
77.  Caronni N, Savino B, Recordati C, et al.: Cancer and Chemokines. Methods 
Mol Biol. 2016; 1393: 87–96.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
78. Massara M, Bonavita O, Mantovani A, et al.: Atypical chemokine receptors in 
cancer: friends or foes? J Leukoc Biol. 2016; 99(6): 927–33.  
PubMed Abstract | Publisher Full Text 
79. Balkwill FR: The chemokine system and cancer. J Pathol. 2012; 226(2): 148–57.  
PubMed Abstract | Publisher Full Text 
80. Puddinu V, Casella S, Radice E, et al.: ACKR3 expression on diffuse large B cell 
lymphoma is required for tumor spreading and tissue infiltration. Oncotarget. 
2017; 8(49): 85068–84.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 7 of 8
F1000Research 2018, 7(F1000 Faculty Rev):95 Last updated: 15 AUG 2018
 Open Peer Review
   Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
 Department of Microbiology and Immunology, Rega Institute for Medical Research, University ofPaul Proost
Leuven, Leuven, Belgium 
 No competing interests were disclosed.Competing Interests:
1
 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Andrew Luster
 No competing interests were disclosed.Competing Interests:
2
 Department of Neuroscience and Pharmacology, Faculty of Health and Medical Science,Mette Rosenkilde
University of Copenhagen, Copenhagen, Denmark 
 No competing interests were disclosed.Competing Interests:
3
Page 8 of 8
F1000Research 2018, 7(F1000 Faculty Rev):95 Last updated: 15 AUG 2018
